Bioeq AG, a Swiss biopharmaceutical company, and Zydus Lifesciences Limited , an innovation-led life-sciences company with an international presence, today announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates has entered into a strategic partnership with Bioeq, for the licensing, supply and commercialization of Bioeq`s Vascular Endothelial Growth Factor (VEGF) inhibitor NUFYMCO®, an interchangeable biosimilar of Lucentis®1 (Ranibizumab) for the U.S. market. The Biologics License Application (BLA) for NUFYMCO® has been approved by U.S.

Researchers at Washington University School of Medicine in St. Louis suggest that common stimulant medications used to treat attention-deficit/hyperactivity disorder (ADHD), such as Ritalin and Adderall, may work in ways scientists didn’t previously understand. The findings challenge the long-held belief that these drugs primarily improve attention by acting directly on the brain’s attention circuits.